Cargando…

The Effect of Docetaxel (Taxotere(®)) on Human Gastric Cancer Cells Exhibiting Low-Dose Radiation Hypersensitivity

Low-dose radiation hypersensitivity (HRS) describes a phenomenon of excessive sensitivity to X ray doses <0.5 Gy. Docetaxel is a taxane shown to arrest cells in the G(2)/M phase of the cell cycle. Some previous studies suggested that HRS might result from the abrogation of the early G(2) checkpoi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Balcer-Kubiczek, Elizabeth K., Attarpour, Mona, Wang, Jian Z., Regine, William F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2008
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161637/ https://www.ncbi.nlm.nih.gov/pubmed/21892291

Ejemplares similares

Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere)
por: Wang, G-S, et al.
Publicado: (2001)

Interaction of Docetaxel (“Taxotere”) with Human P‐Glycoprotein
por: Shirakawa, Katsuro, et al.
Publicado: (1999)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Docetaxel (Taxotere): a new anti-cancer drug with promising potential?
por: Verweij, J.
Publicado: (1994)

Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models
por: Tesei, Anna, et al.
Publicado: (2011)

S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells.
por: Hennequin, C., et al.
Publicado: (1995)

Antitumor Effects of Combining Docetaxel (Taxotere) with the Antivascular Action of Ultrasound Stimulated Microbubbles
por: Goertz, David E., et al.
Publicado: (2012)

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.
por: Sulkes, A., et al.
Publicado: (1994)

Sequential or alternating administration of docetaxel (Taxotere®) combined with FEC in metastatic breast cancer: a randomised phase II trial
por: Spielmann, M, et al.
Publicado: (2002)

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.
por: Sternberg, C. N., et al.
Publicado: (1994)

Physical and chemical stability of Taxotere(®) (docetaxel) one-vial (20 mg/ml) infusion solution following refrigerated storage
por: Hart, M, et al.
Publicado: (2010)

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
por: de Wit, R., et al.
Publicado: (1998)

Safety and efficacy of single‐agent docetaxel (Taxotere) administered weekly in non‐small cell lung carcinoma patients in Korea: An observational study
por: Lim, Sun Min, et al.
Publicado: (2015)

Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
por: Cerny, T., et al.
Publicado: (1994)

Safety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II
por: Kim, Sung-Bae, et al.
Publicado: (2015)

Multicellular Tumor Spheroids for Evaluation of Cytotoxicity and Tumor Growth Inhibitory Effects of Nanomedicines In Vitro: A Comparison of Docetaxel-Loaded Block Copolymer Micelles and Taxotere®
por: Mikhail, Andrew S., et al.
Publicado: (2013)

Decreased DNA-PK activity in human cancer cells exhibiting hypersensitivity to low-dose irradiation
por: Vaganay-Juéry, S, et al.
Publicado: (2000)

Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells
por: Li, Yiwei, et al.
Publicado: (2005)

Influence of the Hypersensitivity to Low Dose Phenomenon on the Tumor Response to Hypofractionated Stereotactic Body Radiation Therapy
por: Le Reun, Eymeric, et al.
Publicado: (2023)

Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel()
por: de Leon, Maria C.B., et al.
Publicado: (2013)

Src tyrosine kinase augments taxotere-induced apoptosis through enhanced expression and phosphorylation of Bcl-2
por: Boudny, V, et al.
Publicado: (2002)

Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response
por: Boniface, Christopher T., et al.
Publicado: (2022)

The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere
por: Li, Jing, et al.
Publicado: (2013)

Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review
por: Pellegrino, Benedetta, et al.
Publicado: (2017)

Corrigendum: Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response
por: Boniface, Christopher T., et al.
Publicado: (2023)

Acute Respiratory Distress Syndrome after Treatment of Metastatic Prostate Cancer with Taxotere: A Case Report and Literature Review
por: Raufi, Ali, et al.
Publicado: (2015)

A magnetic antibody-conjugated nano-system for selective delivery of Ca(OH)(2) and taxotere in ovarian cancer cells
por: Taheri-Ledari, Reza, et al.
Publicado: (2022)

Review of docetaxel in the treatment of gastric cancer
por: Tetzlaff, Eric D, et al.
Publicado: (2008)

Successful Treatment of MMP-9-Expressing Angiosarcoma with Low-Dose Docetaxel and Bisphosphonate
por: Ishibashi, Masaya, et al.
Publicado: (2012)

Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts
por: Thuss-Patience, P C, et al.
Publicado: (2011)

Vascular origins of low‐frequency oscillations in the cerebrospinal fluid signal in resting‐state fMRI: Interpretation using photoplethysmography
por: Attarpour, Ahmadreza, et al.
Publicado: (2021)

High efficacy of combination chemotherapy with S-1 and low-dose docetaxel for the treatment of highly advanced gastric cancer with peritoneal dissemination: A case report
por: ZHU, LUCHENG, et al.
Publicado: (2013)

Hand-foot Syndrome Secondary to Low-dose Docetaxel in a Breast Cancer Patient
por: Kewan, Tariq, et al.
Publicado: (2019)

ARETTA: Assessing Response to Neoadjuvant Taxotere and Subcutaneous Trastuzumab in Nigerian Women With HER2-Positive Breast Cancer: A Study Protocol
por: Ntekim, Atara I., et al.
Publicado: (2020)

Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer
por: Gomez Marti, Juan Luis, et al.
Publicado: (2023)

Docetaxel-induced hand foot syndrome: “No dose is a safe dose”
por: Jain, Ankit, et al.
Publicado: (2012)

Low-dose radiation cancer susceptibility models
por: Mao, Jian-Hua, et al.
Publicado: (2015)

Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study
por: Liu, Dan, et al.
Publicado: (2023)

A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy
por: Spurr, Liam F., et al.
Publicado: (2022)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6vftvpgs7vo2vh6vts1hmptfa5